Loading
Kidney Diseases / Renal Cell Carcinoma / Kidney Neoplasms · Journal article
Annals of Medicine · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective single-center matched cohort of 62 patients (31 PRMN, 31 IPRM) found that primary renal malignancies with concurrent pathologically diagnosed nephropathy showed higher postoperative serum creatinine, lower eGFR, more severe peritumoural renal pathology, and significantly higher all-cause mortality (19.4% vs. 0%, p = 0.007) compared to isolated primary renal malignancies. The findings are clinically suggestive but limited by small size, retrospective design, and exploratory analyses requiring validation.
Retrospective, single-center, 1:1 matched cohort study. 31 patients with primary renal malignancies and pathologically diagnosed concurrent nephropathy and 31 matched controls with isolated primary renal malignancies, aged ≥18 years, with complete pathology reports and postoperative follow-up, treated at Hangzhou TCM Hospital between 2013 and 2023.. Intervention: Surgical treatment for primary renal malignancies (tumour resection); some patients with immune complex-mediated nephritis received postoperative immunosuppressive therapy.. Compared with: Isolated primary renal malignancies without pathologically diagnosed concurrent nephropathy.. n = 62. Single center: Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China..
All-cause mortality rate significantly higher in PRMN group: 19.4% vs. 0% in IPRM group (p = 0.007) Postoperative serum creatinine significantly associated with PRMN (aOR = 1.176, 95% CI: 1.067–1.296; p = 0.001) Postoperative eGFR significantly associated with PRMN (aOR = 1.205, 95% CI: 1.065–1.362; p = 0.003)
All-cause mortality rate significantly higher in PRMN group: 19.4% vs. 0% in IPRM group (p = 0.007)
For clinicians managing primary renal malignancies, this study suggests that concurrent pathologically diagnosed nephropathy identifies a higher-risk subset with worse survival outcomes and more severe renal function deterioration; however, the small sample size and retrospective design warrant caution in clinical application until findings are validated in larger prospective cohorts.
Small single-center matched cohort study (31 per group) with retrospective design and surrogate endpoints; findings on concurrent nephropathy and renal function decline are clinically relevant but require validation in larger prospective studies.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians managing primary renal malignancies, this study suggests that concurrent pathologically diagnosed nephropathy identifies a higher-risk subset with worse survival outcomes and more severe renal function deterioration; however, the small sample size and retrospective design warrant caution in clinical application until findings are validated in larger prospective cohorts.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. This study aimed to compare the clinicopathological features and clinical outcomes between patients with primary renal malignancies with pathologically diagnosed nephropathy (PRMN) and those with isolated primary renal malignancies (IPRMs).Methods. We enrolled 31 patients with PRMN and 31 matched controls with IPRM between 2013 and 2023. Clinical characteristics, tumour pathological features, therapeutic interventions and prognostic outcomes were systematically analysed. Nephropathy was diagnosed by immunofluorescence, immunohistochemistry and light microscopy.Results. Patients in the PRMN group were younger, with a higher proportion of males and those with a smoking history. Preoperative and postoperative serum creatinine (Scr) were significantly higher in the PRMN group than in the IPRM group, while estimated glomerular filtration rate (eGFR) was significantly lower. Peritumoural renal tissues in the PRMN group showed more severe pathological changes, including global glomerulosclerosis (GS), segmental glomerulosclerosis (SS), and interstitial fibrosis and tubular atrophy (IFTA). Tumour treatment modalities did not differ significantly between groups. However, the PRMN group had a significantly higher all-cause mortality rate (19.4% vs. 0%, p = 0.007). Logistic regression showed that postoperative Scr (aOR = 1.176, 95% CI: 1.067-1.296; p = 0.001) and postoperative eGFR (aOR = 1.205, 95% CI: 1.065-1.362; p = 0.003) were significantly associated with PRMN. ROC analysis suggested that preoperative Scr (cutoff = 78.5 μmol/L) had diagnostic value for identifying PRMN. Kaplan-Meier's analysis showed that overall survival and composite endpoint survival were significantly lower in the PRMN group (p < 0.05). In exploratory Cox regression, age showed a potential association with the composite endpoint (HR = 1.138, 95% CI: 1.007-1.286, p = 0.038), though this finding requires validation.Conclusions. Patients with PRMN exhibited distinct clinicopathological characteristics, factors associated with disease progression, and a higher incidence of adverse outcomes compared to those with IPRM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.